Sumitomo Dainippon Pharma Annual Report 2017
89/102

20162017Note: “Other” mainly consists of investment trust.Retirement benet trusts set up for corporate pension plans account for 7.9 percent and 6.6 percent of total plan assets at March 31, 2017 and 2016, respectively.2. Dened contribution plansThe amount of required contributions to the dened contribution plans of the Company and consolidated subsidiaries was ¥2,895 million ($25,848 thousand) and ¥2,992 million for the years ended March 31, 2017 and 2016, respectively.54.3%14.0%5.1%10.5%16.1%100.0%201650.3%17.1%4.8%10.6%17.2%100.0%2017BondsEquity securitiesCash and cash equivalentsGeneral accountOtherTotal8) Plan assetsi) Plan assets comprise:1.0%2.0%3.8 5.8%Discount rateLong-term expected rate of returnEstimated salary increase rate9) Actuarial assumptionsThe principal actuarial assumptions as at March 31, 2017 and 2016 (expressed as weighted averages) were as follows:ii) Long-term expected rate of returnCurrent and target asset allocations, historical and expected returns on various categories of plan assets have been considered in determining the long-term expected rate of return.Under the Japanese Corporate Law (“the Law”) and regulations, the entire amount paid for new shares is required to be designated as common stock. However, a company may, by a resolution of the Board of Directors, designate an amount not exceeding 50% of the price of the new shares as additional paid-in capital, which is included in capital surplus. Under the Law, in cases where a dividend distribution of surplus is made, the smaller of an amount equal to 10% of the dividend or the excess, if any, of 25% of common stock over the total of additional paid-in capital and legal reserve must be set aside as additional paid-in capital or legal reserve. Legal reserve is included in retained earnings in the accompanying consolidated balance sheets. Under the Law, legal reserve and additional paid-in capital could be used to eliminate or reduce a decit by a resolution of the shareholders’ meeting or could be capitalized by a resolution of the Board of Directors. Under the Law, both of these appropriations generally require a resolution of the shareholders’ meeting. Additional paid-in capital and legal reserve may not be distributed as dividends, but may be transferred to other capital surplus and retained earnings respectively, which are potentially available for dividends. The maximum amount that the Company can distribute as dividends is calculated based on the unconsolidated nancial statements of the Company in accordance with the Law and regulations. At the annual shareholders’ meeting held on June 22, 2017, the shareholders approved year-end cash dividends of ¥11.00 ($0.10) per share, amounting to ¥4,370 million ($39,018 thousand). These appropriations have not been accrued in the consolidated nancial statements as of March 31, 2017. Such appropriations are recognized in the period in which they are approved by the shareholders. Together with the interim cash dividends, the total annual dividends were ¥20.00 ($0.18) per share.11. SHAREHOLDERS’ EQUITY1.0 3.2%2.0%3.8 5.8%Sumitomo Dainippon Pharma Co., Ltd. Annual Report 201788

元のページ  ../index.html#89

このブックを見る